[go: up one dir, main page]

NO20010047L - Antivirale makrocykliske forbindelser - Google Patents

Antivirale makrocykliske forbindelser

Info

Publication number
NO20010047L
NO20010047L NO20010047A NO20010047A NO20010047L NO 20010047 L NO20010047 L NO 20010047L NO 20010047 A NO20010047 A NO 20010047A NO 20010047 A NO20010047 A NO 20010047A NO 20010047 L NO20010047 L NO 20010047L
Authority
NO
Norway
Prior art keywords
antiviral
macrocyclic compounds
macrocyclic
compounds
antiviral macrocyclic
Prior art date
Application number
NO20010047A
Other languages
English (en)
Other versions
NO20010047D0 (no
Inventor
Gary James Bridger
Eva Maria Boehringer
Zhongren Wang
Dominique Schols
Renato Tony Skerlj
David Earl Bogucki
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20010047D0 publication Critical patent/NO20010047D0/no
Publication of NO20010047L publication Critical patent/NO20010047L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20010047A 1998-07-08 2001-01-04 Antivirale makrocykliske forbindelser NO20010047L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/111,895 US6506770B1 (en) 1996-06-06 1998-07-08 Antiviral compounds
PCT/CA1999/000619 WO2000002870A1 (en) 1998-07-08 1999-07-08 Antiviral macrocyclic compounds

Publications (2)

Publication Number Publication Date
NO20010047D0 NO20010047D0 (no) 2001-01-04
NO20010047L true NO20010047L (no) 2001-03-01

Family

ID=22341015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010047A NO20010047L (no) 1998-07-08 2001-01-04 Antivirale makrocykliske forbindelser

Country Status (17)

Country Link
US (6) US6506770B1 (no)
EP (1) EP1095031B1 (no)
JP (1) JP4637353B2 (no)
KR (1) KR100778134B1 (no)
CN (2) CN100339080C (no)
AP (1) AP1436A (no)
AU (1) AU767359B2 (no)
BR (1) BR9912524A (no)
CA (1) CA2336634C (no)
HU (1) HUP0102930A3 (no)
IL (1) IL140605A0 (no)
MX (1) MXPA01000137A (no)
NO (1) NO20010047L (no)
NZ (1) NZ509699A (no)
PL (1) PL345516A1 (no)
TR (1) TR200100030T2 (no)
WO (1) WO2000002870A1 (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AU2334301A (en) 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
RU2277092C2 (ru) * 2000-09-15 2006-05-27 Анормед, Инк. Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5
KR20030029997A (ko) * 2000-09-15 2003-04-16 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
US7052676B2 (en) * 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030220341A1 (en) * 2001-12-21 2003-11-27 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
DE602004024871D1 (de) 2003-04-02 2010-02-11 Taigen Biotechnology Co Ltd Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
CN101941964A (zh) 2003-04-22 2011-01-12 阿诺麦德股份有限公司 具有促进功效的趋化因子受体结合的杂环化合物
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
JPWO2005051927A1 (ja) * 2003-11-26 2007-12-06 株式会社クレハ Ｈｉｖ−１感染末梢血単核球の刺激培養によるｃｄ４陽性ｔ細胞の培養方法、及びｈｉｖ−１の増殖阻害剤
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
EP1951046B1 (en) * 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
WO2007036036A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
WO2008029276A2 (en) * 2006-02-02 2008-03-13 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
RU2420284C2 (ru) * 2006-06-12 2011-06-10 Пфайзер Продактс Инк. Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич
MX2009001272A (es) * 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
AR062271A1 (es) * 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
US20090274687A1 (en) * 2008-05-02 2009-11-05 University Of Miami Attenuation of hypoxia induced cardiovascular disorders
WO2010088401A1 (en) * 2009-01-30 2010-08-05 Genzyme Corporation Methods and compositions for treating breast cancer
CA2760292A1 (en) * 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012061662A1 (en) * 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
PL2794626T6 (pl) 2011-12-22 2020-11-02 Glycomimetics, Inc. Związki antagonistyczne E-selektyny
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103058998B (zh) * 2013-01-16 2016-04-13 山东鲁北药业有限公司 一种amd3465的制备工艺
EP3569609A1 (en) 2014-12-03 2019-11-20 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
JP6927882B2 (ja) * 2015-04-02 2021-09-01 プロキシマジェン，リミティド ライアビリティ カンパニー 癌の新治療法
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
WO2017068583A1 (en) * 2015-10-19 2017-04-27 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating neurodegenerative diseases
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11433048B2 (en) 2016-06-16 2022-09-06 Centre National De La Recherche Scientifique CXCR4 receptor-binding compounds useful for increasing interferon level
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
EP3522931A1 (en) 2016-10-07 2019-08-14 GlycoMimetics, Inc. Highly potent multimeric e-selectin antagonists
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
CN111542597A (zh) 2017-10-31 2020-08-14 美真达治疗公司 用于扩增造血干细胞和祖细胞的组合物和方法
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3720494A2 (en) 2017-12-06 2020-10-14 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
JP2021510150A (ja) 2018-01-03 2021-04-15 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 造血幹細胞および前駆細胞の増幅ならびに遺伝性代謝障害の処置のための組成物および方法
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
CA3176979A1 (en) 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
EP1061944B1 (en) 1998-03-13 2004-01-28 The University Of British Columbia Therapeutic chemokine receptor antagonists
DE69932510T2 (de) * 1998-03-24 2007-02-15 Chugai Seiyaku K.K. Vaskularisierungsinhibitoren
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
WO2005002522A2 (en) 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7315917B2 (en) * 2005-01-20 2008-01-01 Sandisk Corporation Scheduling of housekeeping operations in flash memory systems

Also Published As

Publication number Publication date
HUP0102930A3 (en) 2002-06-28
MXPA01000137A (es) 2002-11-29
EP1095031B1 (en) 2013-08-21
CN1308617A (zh) 2001-08-15
US6756391B2 (en) 2004-06-29
CA2336634A1 (en) 2000-01-20
CN1195745C (zh) 2005-04-06
AU767359B2 (en) 2003-11-06
US7414065B2 (en) 2008-08-19
US20040235814A1 (en) 2004-11-25
CN100339080C (zh) 2007-09-26
BR9912524A (pt) 2001-05-02
US7160872B2 (en) 2007-01-09
IL140605A0 (en) 2002-02-10
US6506770B1 (en) 2003-01-14
US7709486B2 (en) 2010-05-04
AU4595999A (en) 2000-02-01
US6872714B1 (en) 2005-03-29
AP1436A (en) 2005-06-22
NO20010047D0 (no) 2001-01-04
NZ509699A (en) 2003-10-31
US20050154005A1 (en) 2005-07-14
JP2002520323A (ja) 2002-07-09
TR200100030T2 (tr) 2001-06-21
AP2001002043A0 (en) 2001-03-31
CN1679562A (zh) 2005-10-12
US20030018189A1 (en) 2003-01-23
PL345516A1 (en) 2001-12-17
US20080287454A1 (en) 2008-11-20
EP1095031A1 (en) 2001-05-02
HUP0102930A2 (hu) 2001-11-28
KR100778134B1 (ko) 2007-11-27
KR20010071764A (ko) 2001-07-31
CA2336634C (en) 2009-05-19
WO2000002870A1 (en) 2000-01-20
JP4637353B2 (ja) 2011-02-23

Similar Documents

Publication Publication Date Title
NO20010047L (no) Antivirale makrocykliske forbindelser
BR9709643A (pt) Compostos antivirais
LTPA2009006I1 (lt) Trombopoetino junginiai
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
EE200100600A (et) FAP-aktiveeritud kasvajavastased ühendid
NO20011745L (no) Forbindelser
PT930302E (pt) Derivados de benzo-sulfona
NO20006520D0 (no) Adenosinderivater
PT1104422E (pt) Derivados de fenilxantina
PT928790E (pt) Derivados de tiazolo
NO20005795D0 (no) Antivirale forbindelser
NO20005006D0 (no) Kalsilytiske forbindelser
NO20006662D0 (no) Fluorfenylresin-forbindelser
PT1056716E (pt) Derivados de ciclo-hexanodiolo
BR9709432A (pt) Composto antivirais
ATE233253T1 (de) Chromanderivate
DK1054867T3 (da) Antivirale midler
NO20011358L (no) Antivirale kombinasjoner
BR9709528A (pt) Compostos antivirais
DK1060183T3 (da) 5-deoxycytidinderivater
PT1123283E (pt) Derivados de tiazole
PT928793E (pt) Derivados de tiazol
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
IT245368Y1 (it) Struttura modulare tascabile

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application